SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ousters Rev8 lidar is drawing attention through integrations and planned deployments in Senecas autonomous wildfire drones, John Deeres orchard machines, and drone-mapping and infrastructure systems, reinforcing the communitys physical-AI growth thesis. Traders are split between optimism about customer traction and scaling production and concern over volatility, valuation, dilution, and execution.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase is under pressure alongside solar peers as traders cite rising Treasury yields and borrowing costs as headwinds for residential solar demand. The debate is split between bearish calls for further declines and dip buyers looking for a rebound, with some also pointing to the IQ SST data-center power opportunity as a longer-term potential catalyst.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is drawing attention as a potential beneficiary of growing demand for AI safety, model evaluation, and agent oversight; traders also cite an unconfirmed report linking the company to Metas Muse. Bulls see opportunity in the AI-data theme and recent momentum, while skeptics question the Meta connection and point to volatility, resistance, and possible share issuance as risks.

Citigroup, Inc. is a holding company, which engages in the provision of financial products and services. It operates through the following segments: Services, Markets, Banking, Wealth, U.S. Personal Banking (USPB), and All Other. The Services segment includes Treasury and Trade Solutions (TTS) which provides an integrated suite of tailored cash management, trade, and working capital solutions to multinational corporations, financial institutions and public sector organizations, and Securities Services, which offers cross-border support for clients, providing on-the-ground local market expertise, post-trade technologies, customized data solutions, and a wide range of securities services solutions that can be tailored to meet client needs. The Markets segment provides corporate, institutional, and public sector clients around the world with a full range of sales and trading services across equities, foreign exchange, rates, spread products, and commodities. The Banking segment offers Investment Banking and Corporate Lending services. The Wealth segment includes Private Bank, Wealth at Work, and Citigold and provides financial services to a range of client segments through banking, lending, mortgages, investment, custody, and trust product offerings. The USPB segment includes Branded Cards and Retail Services, which have proprietary card portfolios and co-branded card portfolios within Branded Cards, and co-brand and private label relationships within Retail Services. The All Other segment consists of activities not assigned to the reportable operating segments, including certain unallocated costs of global functions, other corporate expenses, and net treasury results. The company was founded in 1812 and is headquartered in New York, NY.

Citigroup Inc

Citi is drawing attention ahead of bank earnings, as traders debate how higher yields and weakening economic conditions could affect lending, credit quality, and guidance. Some expect pressure on results and are bearish on bank stocks, while others view the pullback as a buying opportunity and point to bullish options activity.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Papua New Guinea, Australia, Ghana, Suriname, Argentina, Peru, Mexico, Canada, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmont is drawing attention for a sharp move that traders link broadly to bullish sentiment on gold and miners, with many viewing the shares as a hedge against inflation and currency weakness. The moves immediate stock-specific cause is unclear in the discussion, prompting speculation about a leak or other catalyst alongside questions about golds direction.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivaxs pullback is fueling debate over whether buyout hopes have outrun the near-term case for its ulcerative-colitis drug, obefazimod, despite positive Phase 3 data and a planned FDA filing. Bulls see value in the drugs potential and point to Crohns data as a future catalyst, while skeptics say the lack of a deal could leave the shares waiting on clinical and regulatory milestones; some also cite broader biotech weakness.

Bank of America Corp. is a bank and financial holding company, which engages in the provision of banking and nonbank financial services. It operates through the following segments: Consumer Banking, Global Wealth and Investment Management (GWIM), Global Banking, Global Markets, and All Other. The Consumer Banking segment offers credit, banking, and investment products and services to consumers and small businesses. The GWIM segment focuses on solutions to meet clients’ needs through a full set of investment management, brokerage, banking, and retirement products. The Global Banking segment deals with lending-related products and services, integrated working capital management and treasury solutions to clients, and underwriting and advisory services. The Global Markets segment includes sales and trading services, as well as research, to institutional clients across fixed-income, credit, currency, commodity, and equity businesses. The All Other segment consists of asset and liability management activities, equity investments, non-core mortgage loans and servicing activities, the net impact of periodic revisions to the mortgage servicing rights valuation model for both core and non-core MSRs, other liquidating businesses, residual expense allocations and other. The company was founded by Amadeo Peter Giannini in 1904 and is headquartered in Charlotte, NC.

Bank Of America Corp.

Bank of America Corp

Bank of Americas sharp pullback alongside other large banks ahead of quarterly results is driving discussion, with traders pointing to elevated Treasury yields, rate concerns and a softer capital-markets outlook. Some expect further downside, while others see the selloff as overdone and view the shares as oversold ahead of earnings.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Novartiss failed Phase 3 trial for a competing DM1 therapy has prompted concern that reducing DMPK may not translate into clinical benefit, weighing on Sarepta amid read-through selling. Traders disagree on how much that result applies to Sareptas differently delivered SRP-1003, with its upcoming DM1 data viewed as a key test and potential catalyst.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

SCHD is drawing attention as investors discuss a rotation between growth stocks and dividend-focused, defensive holdings, with many viewing the ETF as a steadier counterweight to tech volatility. Traders are split between buying dips for long-term income and questioning its recent pullbacks, which some attribute to rising Treasury yields making bonds more competitive.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Barclays downgrade of Joby, citing cash burn and doubts about manufacturing capacity, is driving the selloff and comparisons with its upgraded rival Archer. Traders disagree over whether the concerns are justified or the downgrade is a shakeout, with some buying the dip and others moving toward Archer.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Brief Healthcare: PolyPeptide: Strategic Review Is Real, But the Setup Isn’t Clean and more

In this briefing: PolyPeptide: Strategic Review Is Real, But the Setup Isn’t Clean Aequitas: Integris Medtech Ltd Pre-IPO: Medtech Platform with Strong Growth but Elevated Leverage Tetratherix Limited - Commercialising the Platform Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 Primer: Kopran Ltd (KOP IN) - Apr 2026 1. PolyPeptide: Strategic Review Is Real, But the Setup Isn’t Clean PolyPeptide is in a credible strategic review process, but at CHF37.25 the market already prices a 58.3% deal probability, leaving limited upside relative to downside risk in a break scenario. While a full re-rating implies valuation above CHF 50, sponsor return constraints anchor a realistic takeout in the low-to-mid 40s, supported by LBO analysis and peer multiple comparisons. The controlling shareholder structure introduces a third outcome where minorities may not receive a full premium, meaning “a deal” does not necessarily translate into immediate value crystallisation for investors. 2. Aequitas: Integris Medtech Ltd Pre-IPO: Medtech Platform with Strong Growth but Elevated Leverage Integris Medtech Limited (1234518D IN) (IML) plans to raise around US$340m in its upcoming IPO.

Brief Healthcare: Tetratherix Limited - Commercialising the Platform and more

In this briefing: Tetratherix Limited - Commercialising the Platform Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 Primer: Kopran Ltd (KOP IN) - Apr 2026 Sirius (靖因生物) Pre-IPO: Pipeline Prioritization and Competitor Updates TransThera Placement (2617 HK): Tinengotinib Alone Can’t Signal Any Major Upheaval of Fortunes 1. Tetratherix Limited - Commercialising the Platform Tetratherix Limited (ASX:TTX) is an Australian biomedical company commercialising a proprietary polymer platform, Tetramatrix, across four franchises: bone regeneration, tissue spacing, tissue healing and precision medicine. Tetramatrix is a novel fully synthetic, water-based injectable polymer that transitions from a liquid to a solid matrix/scaffold when it enters the human body (at 37°C). As the product mimics natural tissue, it offers potential advantages versus existing animal-derived solutions that are prone to immune responses like inflammation. 2. Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 Solara is a pure-play Active Pharmaceutical Ingredients (API) manufacturer emerging from a significant operational and financial reset, showing early signs of a turnaround with improved profitability and cash flows in the most recent fiscal year.

Brief Equities Bottom-Up: Primer: Arvind Fashions (ARVINDFA IN) - Apr 2026 and more

In this briefing: Primer: Arvind Fashions (ARVINDFA IN) - Apr 2026 Primer: Vedant Fashions (MANYAVAR IN) - Apr 2026 Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 Primer: Sunwoda Electronic Co Ltd A (300207 CH) - Apr 2026 Primer: Kopran Ltd (KOP IN) - Apr 2026 1. Primer: Arvind Fashions (ARVINDFA IN) - Apr 2026 Arvind Fashions holds a strong position in India's apparel market through a focused portfolio of high-recognition, premium, and bridge-to-luxury brands, most notably the licensed brand U.S. Polo Assn., which is a significant revenue driver. The company is pursuing a clear growth strategy centered on expanding its retail footprint via an asset-light franchise model, enhancing its omnichannel capabilities, and growing its direct-to-consumer (D2C) business to improve margins and customer engagement. After a period of portfolio rationalization and financial volatility, the company has shown signs of a turnaround with improving profitability metrics and a strengthened balance sheet, although it faces intense competition and risks associated with licensed brand agreements.

Brief Growth Ideas: Aequitas: Rentmojo Ltd Pre-IPO Tearsheet and more

In this briefing: Aequitas: Rentmojo Ltd Pre-IPO Tearsheet Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 Primer: Sunwoda Electronic Co Ltd A (300207 CH) - Apr 2026 Primer: Kopran Ltd (KOP IN) - Apr 2026 X-Energy Inc. (XE): Amazon Backed Advanced Nuclear Reactor Tech Company Sets Terms for IPO 1. Aequitas: Rentmojo Ltd Pre-IPO Tearsheet Rentmojo Ltd (RMJL IN) s looking to raise about US$126m in its upcoming India IPO. The deal will be run by Axis, IIFL and Motilal Oswal. Rentmojo operates a technology-driven, full-stack direct-to-consumer online rental and subscription platform for furniture and appliances in India, spanning across category management, designing, procurement, refurbishment, servicing, reverse logistics and multi-cycle redeployment. According to Redseer, it was the largest home furniture and appliances online rental and subscription platform(based on live subscribers) as of FY25 and Sep 30, 2025, and subscription revenue(during FY25). 2. Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 Solara is a pure-play Active Pharmaceutical Ingredients (API) manufacturer emerging from a significant operational and financial reset, showing early signs of a turnaround with improved profitability and cash flows in the most recent fiscal year.

Brief India: Aequitas: Rentmojo Ltd Pre-IPO Tearsheet and more

In this briefing: Aequitas: Rentmojo Ltd Pre-IPO Tearsheet Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 Primer: Kopran Ltd (KOP IN) - Apr 2026 Primer: Home First Finance (HOMEFIRS IN) - Apr 2026 HSIE Results Daily: ICICI Prudential Life Insurance Company 1. Aequitas: Rentmojo Ltd Pre-IPO Tearsheet Rentmojo Ltd (RMJL IN) s looking to raise about US$126m in its upcoming India IPO. The deal will be run by Axis, IIFL and Motilal Oswal. Rentmojo operates a technology-driven, full-stack direct-to-consumer online rental and subscription platform for furniture and appliances in India, spanning across category management, designing, procurement, refurbishment, servicing, reverse logistics and multi-cycle redeployment. According to Redseer, it was the largest home furniture and appliances online rental and subscription platform(based on live subscribers) as of FY25 and Sep 30, 2025, and subscription revenue(during FY25). 2. Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 Solara is a pure-play Active Pharmaceutical Ingredients (API) manufacturer emerging from a significant operational and financial reset, showing early signs of a turnaround with improved profitability and cash flows in the most recent fiscal year.

Brief Equities Bottom-Up: Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 and more

In this briefing: Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 Primer: Sunwoda Electronic Co Ltd A (300207 CH) - Apr 2026 Primer: Kopran Ltd (KOP IN) - Apr 2026 Sony Financial Group (8729) - Cheap Vs Peers and Growing Out of Its ROE Hole Primer: Aspial Corp Ltd (ASP SP) - Apr 2026 1. Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 Solara is a pure-play Active Pharmaceutical Ingredients (API) manufacturer emerging from a significant operational and financial reset, showing early signs of a turnaround with improved profitability and cash flows in the most recent fiscal year. The company holds a strong position in several key products, including being a global leader in Ibuprofen, and benefits from a strong regulatory track record with approvals from major authorities like the US FDA and EDQM, which is critical for serving highly regulated markets. High operational gearing, significant historical earnings volatility, and intense competition in the generic API space present considerable risks, but the company's strategic shift towards higher-value products and improving financial health offer potential upside.

Brief India: Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 and more

In this briefing: Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 Primer: Kopran Ltd (KOP IN) - Apr 2026 Primer: Home First Finance (HOMEFIRS IN) - Apr 2026 HSIE Results Daily: ICICI Prudential Life Insurance Company Pharmaceuticals: IPM: 11% growth in Mar-26, 10% in FY26 1. Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 Solara is a pure-play Active Pharmaceutical Ingredients (API) manufacturer emerging from a significant operational and financial reset, showing early signs of a turnaround with improved profitability and cash flows in the most recent fiscal year. The company holds a strong position in several key products, including being a global leader in Ibuprofen, and benefits from a strong regulatory track record with approvals from major authorities like the US FDA and EDQM, which is critical for serving highly regulated markets. High operational gearing, significant historical earnings volatility, and intense competition in the generic API space present considerable risks, but the company's strategic shift towards higher-value products and improving financial health offer potential upside.

Brief Growth Ideas: Primer: Sunwoda Electronic Co Ltd A (300207 CH) - Apr 2026 and more

In this briefing: Primer: Sunwoda Electronic Co Ltd A (300207 CH) - Apr 2026 Primer: Kopran Ltd (KOP IN) - Apr 2026 X-Energy Inc. (XE): Amazon Backed Advanced Nuclear Reactor Tech Company Sets Terms for IPO Sony Financial Group (8729) - Cheap Vs Peers and Growing Out of Its ROE Hole Sirius (靖因生物) Pre-IPO: Pipeline Prioritization and Competitor Updates 1. Primer: Sunwoda Electronic Co Ltd A (300207 CH) - Apr 2026 Sunwoda is a global leader in lithium-ion batteries, with diversified exposure across consumer electronics (3C), electric vehicles (EV), and energy storage systems (ESS), positioning it to capitalize on broad-based electrification trends. The company exhibits a strong growth trajectory, evidenced by a 3-year revenue CAGR of 14.52% and net income CAGR of 17.05%. However, this growth is capital-intensive, resulting in consistently negative free cash flow and a lower resilience score. Strategic expansion into high-growth EV and ESS markets complements its established leadership in 3C batteries, but the company faces intense competition, margin pressure, and significant operational risks, including supply chain volatility and customer quality disputes.

Brief Equities Bottom-Up: Primer: Kopran Ltd (KOP IN) - Apr 2026 and more

In this briefing: Primer: Kopran Ltd (KOP IN) - Apr 2026 Sony Financial Group (8729) - Cheap Vs Peers and Growing Out of Its ROE Hole Primer: Aspial Corp Ltd (ASP SP) - Apr 2026 Primer: Aspial Lifestyle (ASPL SP) - Apr 2026 Primer: Home First Finance (HOMEFIRS IN) - Apr 2026 1. Primer: Kopran Ltd (KOP IN) - Apr 2026 Kopran is an established, integrated pharmaceutical company with a dual focus on Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDF), leveraging over 60 years of experience. The company has a strong global presence, exporting to over 60 countries. The company's financial performance shows consistent long-term revenue growth, but has been marred by recent margin pressure and a significant decline in 3-year net income and EPS. Negative free cash flow, driven by capital expenditures for capacity expansion, is a key concern. Strategically, Kopran is focused on expanding its API capacity, developing niche products, and reducing its reliance on Chinese raw materials.

Brief Growth Ideas: Primer: Kopran Ltd (KOP IN) - Apr 2026 and more

In this briefing: Primer: Kopran Ltd (KOP IN) - Apr 2026 X-Energy Inc. (XE): Amazon Backed Advanced Nuclear Reactor Tech Company Sets Terms for IPO Sony Financial Group (8729) - Cheap Vs Peers and Growing Out of Its ROE Hole Sirius (靖因生物) Pre-IPO: Pipeline Prioritization and Competitor Updates Primer: Aspial Corp Ltd (ASP SP) - Apr 2026 1. Primer: Kopran Ltd (KOP IN) - Apr 2026 Kopran is an established, integrated pharmaceutical company with a dual focus on Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDF), leveraging over 60 years of experience. The company has a strong global presence, exporting to over 60 countries. The company's financial performance shows consistent long-term revenue growth, but has been marred by recent margin pressure and a significant decline in 3-year net income and EPS. Negative free cash flow, driven by capital expenditures for capacity expansion, is a key concern. Strategically, Kopran is focused on expanding its API capacity, developing niche products, and reducing its reliance on Chinese raw materials.

Kopran Ltd. is a holding company, which engages in the manufacturing of pharmaceuticals and related products. It operates through the following business units: Formulations, and Active Pharmaceutical Ingredients. The firm's products include Amyn, Lokit, and Ciproquin. The company was founded on April 26, 1958 and is headquartered in Mumbai, India.

Current Price	249.50
Prev Close	256.00
Open	253.40
Dividend Yield	2.78%
50-Day Moving Average	231.66
Beta	-0.04
Avg. Volume	2.32M
PE Ratio	48.52

52-Week High	295.83
52-Week Low	107.00
Market Capitalization	12.27B
EPS (Annual)	5.33
Price to Book	2.29
Revenue Per Employee	5.86M

Feed

News

Sentiment

Fundamentals

Info

KOPRAN.NSE Fundamentals